• Application of photodynamic therapy with 5-aminolevulinic acid to extracorporeal photopheresis in the treatment of patients with chronic graft-versus-host disease: A first-in-human study 

      Christensen, Eidi; Foss, Olav A.; Quist-Paulsen, Petter; Staur, Ingrid; Pettersen, Frode; Holien, Toril; Juzenzas, Petras; Qian, Peng (Peer reviewed; Journal article, 2021)
      Extracorporeal photopheresis (ECP), an immunomodulatory therapy for the treatment of chronic graft-versus-host disease (cGvHD), exposes isolated white blood cells to photoactivatable 8-methoxypsoralen (8-MOP) and UVA light ...
    • Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age 

      Rank, Cecilie Utke; Wolthers, Benjamin Ole; Grell, Kathrine; Albertsen, Birgitte K.; Frandsen, Thomas L.; Overgaard, U.; Toft, Nina; Nielsen, Ove Juul; Wehner, Peder S.; Harila-Saari, Arja; Heyman, Mats M.; Malmros, Johan; Abrahamsson, Jonas; Norén-Nyström, Ulrika; Tomaszewska-Toporska, Beata; Lund, Bendik; Jarvis, Kirsten Brunsvig; Quist-Paulsen, Petter; Vaitkeviciene, Goda; Griškevičius, Laimonas; Taskinen, Mervi; Wartiovaara-Kautto, Ulla; Lepik, Kristi; Punab, Mari; Jónsson, Ólafur G.; Schmiegelow, Kjeld (Journal article; Peer reviewed, 2020)
      PURPOSE Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure ...
    • Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients – 30 months follow-up 

      Larsen, Trine-Lise; Garresori, Herish; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege; Jacobsen, Eva-Marie; Quist-Paulsen, Petter; Porojnicu, Alina Carmen; Ree, Anne Hansen; Torfoss, Dag; Velle, Elin Osvik; Wik, Hilde Skuterud; Ghanima, Waleed; Sandset, Per Morten; Dahm, Anders Erik A (Peer reviewed; Journal article, 2022)
      Background - There are no data on the effect of low‐dose anticoagulation as secondary prophylaxis for venous thromboembolism (VTE) in cancer patients. We assessed the efficacy and safety of low‐dose apixaban for 30 months, ...
    • Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism 

      Hannevik, Trine-Lise; Brekke, Jorunn; Enden, Tone Rønnaug; Frøen, Hege; Ahmed, Herish; Jacobsen, Eva-Marie; Quist-Paulsen, Petter; Porojnicu, Alina Carmen; Ree, Anne Hansen; Torfoss, Dag; Velle, Elin Osvik; Wik, Hilde Skuterud; Ghanima, Waleed Khalid; Sandset, Per Morten; Dahm, Anders Erik A (Peer reviewed; Journal article, 2020)
      Introduction: The direct oral anti-coagulants (DOAC) edoxaban and rivaroxaban are suggested treatment alternatives for cancer-associated venous thromboembolism (VTE) together with low molecular-weight heparins. New studies ...